Are Epigral latest results good or bad?

Epigral has reported its financial results for the quarter ending March 2025, with the announcement made on May 5, 2025. The company has shown a notable year-on-year growth in Profit After Tax (PAT), reaching Rs 190.52 crore, which reflects a growth of 50.79%. This suggests a strong near-term outlook for the company. Additionally, the operating profit to interest ratio has reached its highest level in the last five quarters at 14.73 times, indicating effective management of interest payments.
On the sales side, Epigral reported net sales of Rs 1,272.87 crore for the latest six months, marking a year-on-year growth of 27.78%. However, the company faced challenges in the most recent quarter, with net sales experiencing a quarter-on-quarter decline of 2.73%. The consolidated net profit also saw a quarter-on-quarter decrease of 16.15%.

Furthermore, interest costs have surged dramatically, indicating a significant rise in borrowings, which could impact future financial performance. Overall, while Epigral has demonstrated strong annual growth metrics, the recent quarterly results reflect some operational challenges. It is also noted that the company saw an adjustment in its evaluation over the past three months.